Curcumin targets in inflammation and cancer

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 2, 2015, Pages 88-96

  Deguchi, Atsuko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Bioavailability; Cancer; Curcumin; Inflammation; NF B; Rupture

Indexed keywords

AMYLOID A PROTEIN; BETA CATENIN; CALGRANULIN A; CURCUMIN; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN MD 2; PROTEIN P16; PROTEIN P53; RESISTIN; STAT PROTEIN; STAT3 PROTEIN; STROMELYSIN 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AUTACOID;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; MOLECULAR DOCKING; MULTIPLE MYELOMA; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR GROWTH; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CURCUMIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84930512797     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530315666150316120458     Document Type: Article

References (85)

1. [1] Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol., 2008, 75, 787-809.
2. [2] Strimpakos, A.S.; Sharma, R.A. (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid .Redox. Signal, 2008, 10, 511-545.
3. [3] Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer. Res., 2003, 23, 363-398.
4. [4] Sandur, S.K.; Pandey, M.K.; Sung, B.; Ahn, K.S.; Murakami, A.; Sethi, G.; Limtrakul, P.; Badmaev, V.; Aggarwal, B.B. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis, 2007, 28, 1765-1773.
5. [5] Balkwill, F.; Mantovani, A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 2010, 87, 401-406.
6. [6] Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
7. [7] Chaturvedi, M. M.; Sung, B.; Yadav, V. R.; Kannappan, R.; Aggarwal, B.B. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene., 2011, 30, 1615-1630.
8. [8] Perkins, N.D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer, 2012, 12, 121-132.
9. [9] Frantz, S. Drug discovery: playing dirty. Nature, 2005, 437, 942-943.
10. [10] Mencher, S.K.; Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC. Clin. Pharmacol. 2005, 5, 3.
11. [11] Ramsewak, R.S.; DeWitt, D.L.; Nair, M.G. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine, 2000, 7, 303-308.
12. [12] Jobin, C.; Bradham, C.A.; Russo, M.P.; Juma, B.; Narula, A.S.; Brenner, D.A.; Sartor, R.B. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol. 1999, 163, 3474-3483.
13. [13] Rao, C. V.; Rivenson, A.; Simi, B.; Reddy, B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res., 1995, 55, 259-266.
14. [14] Pereira, M. A.; Grubbs, C.J.; Barnes, L.H.; Li, H.; Olson, G.R.; Eto, I.; Juliana, M.; Whitaker, L.M.; Kelloff, G.J.; Steele, V.E.; Lubet, R.A. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis, 1996, 17, 1305-1311.
15. [15] Sidhu, G.S.; Singh, A.K.; Thaloor, D.; Banaudha, K.K.; Patnaik, G. K.; Srimal, R.C.; Maheshwari, R.K. Enhancement of wound healing by curcumin in animals. Wound Repair Regen, 1998, 6, 167-177.
16. [16] Sidhu, G.S.; Mani, H.; Gaddipati, J.P.; Singh, A.K.; Seth, P.; Banaudha, K.K.; Patnaik, G.K.; Maheshwari, R.K. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen, 1999, 7, 362-374.
17. [17] Sharma, O.P. Antioxidant activity of curcumin and related compounds. Biochem. Pharmacol., 1976, 25, 1811-1812.
18. [18] Toda, S.; Miyase, T.; Arichi, H.; Tanizawa, H.; Takino, Y. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem. Pharm. Bull., 198533, 1725-1728.
19. [19] Marcu, M.G.; Jung, Y.J.; Lee, S.; Chung, E.J.; Lee, M.J.; Trepel, J.; Neckers, L. (2006) Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem., 2006, 2, 169-174.
20. [20] Selvam, C.; Jachak, S.M.; Thilagavathi, R.; Chakraborti, A.K. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg. Med. Chem. Lett., 2005, 15, 1793-1797.
21. [21] Padhye, S.; Banerjee, S.; Chavan, D.; Pandye, S.; Swamy, K.V.; Ali, S.; Li, J.; Dou, Q.P.; Sarkar, F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res., 2009, 26, 2438-2445.
22. [22] Dinarello, C.A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev., 2006, 25, 307-313.
23. [23] Plummer, S.M.; Holloway, K.A.; Manson, M.M.; Munks, R.J.; Kaptein, A.; Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 1999, 18, 6013-6020.
24. [24] Goel, A.; Boland, C. R.; Chauhan, D. P. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett172, 111-118.
25. [25] Shankar, S.; Chen, Q.; Sarva, K.; Siddiqui, I.; Srivastava, R.K. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J. Mol. Signal., 2007, 2, 10.
26. [26] Mukhopadhyay, A.; Banerjee, S.; Stafford, L.J.; Xia, C.; Liu, M.; Aggarwal, B.B. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene, 2002, 21, 8852-8861.
27. [27] Cohen, A.N.; Veena, M.S.; Srivatsan, E.S.; Wang, M.B. Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch. Otolaryngol. Head Neck Surg., 2009, 135, 190-197.
28. [28] Wang, X.; Wang, Q.; Ives, K.L.; Evers, B.M. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin. Cancer Res., 2006, 12, 5346-55.
29. [29] Aggarwal, S.; Takada, Y.; Singh, S.; Myers, J.N.; Aggarwal, B.B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int. J. Cancer, 2004, 111, 679-692.
30. [30] Kawai, T.; Akira, S. TLR signaling. Semin. Immunol. 2007, 19, 24-32.
31. [31] Youn, H.S.; Saitoh, S.I.; Miyake, K.; Hwang, D.H. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem. Pharmacol., 2006, 72, 62-69.
32. [32] Gradisar, H.; Keber, M.M.; Pristovsek, P.; Jerala, R. MD-2 as the target of curcumin in the inhibition of response to LPS. J. Leukoc. Biol., 2007, 82, 968-974.
33. [33] Wang, X.; Loram, L.C.; Ramos, K.; de Jesus, A.J.; Thomas, J.; Cheng, K.; Reddy, A.; Somogyi, A.A.; Hutchinson, M.R.; Watkins, L. R.; Yin, H. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc. Natl. Acad. Sci., USA, 2012109, 6325-6330.
34. [34] Bharti, A.C.; Donato, N.; Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 2003, 171, 3863-3871.
35. [35] Kumar, A.; Dhawan, S.; Mukhopadhyay, A.; Aggarwal, B.B. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NFkappaB. FEBS. Lett. 1999 ,462, 140-144.
36. [36] Lin, L.I.; Ke, Y.F.; Ko, Y.C.; Lin, J.K. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology, 1998, 55, 349-353.
37. [37] Kim, M.S.; Kang, H.J.; Moon, A. Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch. Pharm. Res., 2001, 24, 349-354.
38. [38] Gonzalez, F.; Rote, N.S.; Minium, J.; Kirwan, J.P. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J. Clin. Endocrino.l Metab., 2006, 91, 1508-1512.
39. [39] Ajuwon, K.M.; Spurlock, M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288, R1220-1225.
40. [40] Ouchi, N.; Kihara, S.; Arita, Y.; Okamoto, Y.; Maeda, K.; Kuriyama, H.; Hotta, K.; Nishida, M.; Takahashi, M.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMPdependent pathway. Circulation, 2000, 102, 1296-301.
41. [41] Arun, N.; Nalini, N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum. Nutr. 2002, 57, 41-52.
42. [42] Murugan, P.; Pari, L. Influence of tetrahydrocurcumin on hepatic and renal functional markers and protein levels in experimental type 2 diabetic rats. Basic Clin. Pharmacol. Toxicol, 2007, 101, 241-245.
43. [43] El-Moselhy, M.A.; Taye, A.; Sharkawi, S.S.; El-Sisi, S.F.; Ahmed, A.F. The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-alpha and free fatty acids. Food Chem. Toxicol, 2011, 49, 1129-40.
44. [44] Steigerwalt, R.; Nebbioso, M.; Appendino, G.; Belcaro, G.; Ciammaichella, G.; Cornelli, U.; Luzzi, R.; Togni, S.; Dugall, M.; Cesarone, M.R.; Ippolito, E.; Errichi, B.M.; Ledda, A.; Hosoi, M.; Corsi, M. Meriva(R), a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med., 2012, 54, (1 Suppl 4), 11-16.
45. [45] Chuengsamarn, S.; Rattanamongkolgul, S.; Phonrat, B.; Tungtrongchitr, R.; Jirawatnotai, S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J. Nutr. Biochem, 2014, 25, 144-50.
46. [46] Skillrud, D.M.; Offord, K.P.; Miller, R.D. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann. Intern. Med. 1986, 105, 503-507.
47. [47] Tockman, M.S.; Anthonisen, N.R.; Wright, E.C.; Donithan, M.G. Airways obstruction and the risk for lung cancer. Ann. Intern. Med. 1987, 106, 512-518.
48. [48] Moghaddam, S.J.; Barta, P.; Mirabolfathinejad, S.G.; Ammar-Aouchiche, Z.; Garza, N.T.; Vo, T.T.; Newman, R.A.; Aggarwal, B.B.; Evans, C.M.; Tuvim, M.J.; Lotan, R.; Dickey, B.F. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis, 2009, 30, 1949-1956.
49. [49] Deguchi, Y.; Andoh, A.; Inatomi, O.; Yagi, Y.; Bamba, S.; Araki, Y.; Hata, K.; Tsujikawa, T.; Fujiyama, Y. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig. Dis. Sci., 2007, 52, 2993-2998.
50. [50] Holt, P.R.; Katz, S.; Kirshoff, R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci., 2005, 50, 2191-2193.
51. [51] Hanai, H.; Iida, T.; Takeuchi, K.; Watanabe, F.; Maruyama, Y.; Andoh, A.; Tsujikawa, T.; Fujiyama, Y.; Mitsuyama, K.; Sata, M.; Yamada, M.; Iwaoka, Y.; Kanke, K.; Hiraishi, H.; Hirayama, K.; Arai, H.; Yoshii, S.; Uchijima, M.; Nagata, T.; Koide, Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol., 2006, 4, 1502-1506.
52. [52] Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell. 2000100, 57-70.
53. [53] Hanahan, D.; Weinberg, R.A., Hallmarks of cancer: the next generation. Cell. 2011, 144, 646-674.
54. [54] Aggarwal, B.B.; Vijayalekshmi, R.V.; Sung, B. Targeting inflammatory pathways for prevention and therapy of cancer: shortterm friend, long-term foe. Clin. Cancer Res., 2009, 15, 425-430.
55. [55] Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell. Biol., 2006, 8, 1369-1375.
56. [56] Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Miyake, K.; Shibuya, M.; Akira, S.; Aburatani, H.; Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell. Biol., 2008, 10, 1349-1355.
57. [57] Deguchi, A.; Tomita, T.; Omori, T.; Komatsu, A.; Ohto, U.; Takahashi, S.; Tanimura, N.; Akashi-Takamura, S.; Miyake, K.; Maru, Y. Serum amyloid A3 binds MD-2 to activate p38 and NFkappaB pathways in a MyD88-dependent manner. J. Immunol., 2013, 191, 1856-1864.
58. [58] Corpet, D.E.; Tache, S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr. Cancer, 2002, 43, 1-21.
59. [59] Huang, M.T.; Deschner, E.E.; Newmark, H.L.; Wang, Z.Y.; Ferraro, T.A.; Conney, A.H. Effect of dietary curcumin and ascorbyl palmitate on azoxymethanol-induced colonic epithelial cell proliferation and focal areas of dysplasia. Cancer Lett, 1992, 64, 117-121.
60. [60] Rocks, N.; Bekaert, S.; Coia, I.; Paulissen, G.; Gueders, M.; Evrard, B.; Van Heugen, J.C.; Chiap, P.; Foidart, J.M.; Noel, A.; Cataldo, D. Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br. J. Cancer, 2012, 107, 1083-1092.
61. [61] Shishodia, S.; Aggarwal, B.B. Nuclear factor-kappaB activation: a question of life or death. J. Biochem. Mol. Biol. 2002, 35, 28-40.
62. [62] Chauhan, D.; Hideshima, T.; Mitsiades, C.; Richardson, P.; Anderson, K.C. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther., 2005, 4, 686-692.
63. [63] Wan, S.B.; Yang, H.; Zhou, Z.; Cui, Q.C.; Chen, D.; Kanwar, J.; Mohammad, I.; Dou, Q.P.; Chan, T.H. Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors. Int. J. Mol. Med., 2010, 26, 447-455.
64. [64] Bharti, A.C.; Takada, Y.; Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol., 2004, 172, 5940-5947.
65. [65] Dorai, T.; Dutcher, J.P.; Dempster, D.W.; Wiernik, P.H. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate, 2004, 60, 1-17.
66. [66] Hartojo, W.; Silvers, A.L.; Thomas, D.G.; Seder, C.W.; Lin, L.; Rao, H.; Wang, Z.; Greenson, J.K.; Giordano, T.J.; Orringer, M. B.; Rehemtulla, A.; Bhojani, M.S.; Beer, D.G.; Chang, A.C. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl. Oncol., 2010, 3, 99-108.
67. [67] Sandur, S.K.; Deorukhkar, A.; Pandey, M.K.; Pabon, A.M.; Shentu, S.; Guha, S.; Aggarwal, B.B.; Krishnan, S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 534-542.
68. [68] Cheng, A.L.; Hsu, C. H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T. S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Res., 2000, 21, 2895-2900.
69. [69] Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64, 353-356.
70. [70] Gota, V.S.; Maru, G.B.; Soni, T.G.; Gandhi, T.R.; Kochar, N.; Agarwal, M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem., 2010, 58, 2095-2099.
71. [71] Wang, D.; Veena, M.S.; Stevenson, K.; Tang, C.; Ho, B.; Suh, J. D.; Duarte, V.M.; Faull, K.F.; Mehta, K.; Srivatsan, E.S.; Wang, M.B. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKTindependent pathway. Clin. Cancer Res., 2008, 14, 6228-6236.
72. [72] Anand, P.; Nair, H.B.; Sung, B.; Kunnumakkara, A.B.; Yadav, V. R.; Tekmal, R.R.; Aggarwal, B.B. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol, 2010, 79, 330-338.
73. [73] Kanai, M.; Imaizumi, A.; Otsuka, Y.; Sasaki, H.; Hashiguchi, M.; Tsujiko, K.; Matsumoto, S.; Ishiguro, H.; Chiba, T. Doseescalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Pharmacol., 2012, 69, 65-70.
74. [74] Kanai, M.; Yoshimura, K.; Asada, M.; Imaizumi, A.; Suzuki, C.; Matsumoto, S.; Nishimura, T.; Mori, Y.; Masui, T.; Kawaguchi, Y.; Yanagihara, K.; Yazumi, S.; Chiba, T.; Guha, S.; Aggarwal, B.B. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol,, 2011, 68, 157-164.
75. [75] Sasaki, H.; Sunagawa, Y.; Takahashi, K.; Imaizumi, A.; Fukuda, H.; Hashimoto, T.; Wada, H.; Katanasaka, Y.; Kakeya, H.; Fujita, M.; Hasegawa, K.; Morimoto, T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 2011, 34, 660-665.
76. [76] Maiti, K.; Mukherjee, K.; Gantait, A.; Saha, B.P.; Mukherjee, P.K. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm., 2007, 330, 155-163.
77. [77] Adams, B.K.; Cai, J.; Armstrong, J.; Herold, M.; Lu, Y.J.; Sun, A.; Snyder, J.P.; Liotta, D.C.; Jones, D.P.; Shoji, M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs, 2005, 16, 263-275.
78. [78] Shibata, H.; Yamakoshi, H.; Sato, A.; Ohori, H.; Kakudo, Y.; Kudo, C.; Takahashi, Y.; Watanabe, M.; Takano, H.; Ishioka, C.; Noda, T.; Iwabuchi, Y. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci., 2009, 100, 956-960.
79. [79] Tan, X.; Sidell, N.; Mancini, A.; Huang, R.P.; Shenming, W.; Horowitz, I.R.; Liotta, D.C.; Taylor, R.N.; Wieser, F. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod. Sci., 2010, 17, 931-940.
80. [80] Kanai, M.; Otsuka, Y.; Otsuka, K.; Sato, M.; Nishimura, T.; Mori, Y.; Kawaguchi, M.; Hatano, E.; Kodama, Y.; Matsumoto, S.; Murakami, Y.; Imaizumi, A.; Chiba, T.; Nishihira, J.; Shibata, H.A phase. I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother. Pharmacol., 2013, 71, 1521-1530.
81. [81] Sato, A.; Kudo, C.; Yamakoshi, H.; Uehara, Y.; Ohori, H.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Curcumin analog GO-Y030 is a novel inhibitor of IKKbeta that suppresses NF-kappaB signaling and induces apoptosis. Cancer Sci., 2011, 102, 1045-1051.
82. [82] Lin, L.; Liu, Y.; Li, H.; Li, P. K.; Fuchs, J.; Shibata, H.; Iwabuchi, Y.; Lin, J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer, 2011, 105, 212-220.
83. [83] Bao, B.; Ali, S.; Banerjee, S.; Wang, Z.; Logna, F.; Azmi, A.S.; Kong, D.; Ahmad, A.; Li, Y.; Padhye, S.; Sarkar, F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res., 2012, 72, 335-345.
84. [84] Ali, S.; Ahmad, A.; Banerjee, S.; Padhye, S.; Dominiak, K.; Schaffert, J.M.; Wang, Z.; Philip, P.A.; Sarkar, F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res., 2010, 70, 3606-3617.
85. [85] Lao, C.D.; Ruffin, M.T. ; Normolle, D.; Heath, D.D.; Murray, S. I.; Bailey, J.M.; Boggs, M.E.; Crowell, J.; Rock, C.L.; Brenner, D. E. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med., 2006, 6, 10